Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer

Rationale: Aberrant androgen receptor (AR) signaling via full-length AR (AR-FL) and constitutively active AR variant 7 (AR-V7) plays a key role in the development of castration-resistant prostate cancer (CRPC) and resistance to hormone therapies. Simultaneous targeting of AR-FL and AR-V7 may be a pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Moon, Sue Jin, Jeong, Byong Chang, Kim, Hwa Jin, Lim, Joung Eun, Kim, Hye-Jeong, Kwon, Ghee Young, Jackman, Joshua A., Kim, Jeong Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738850/
https://www.ncbi.nlm.nih.gov/pubmed/33391515
http://dx.doi.org/10.7150/thno.51478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738850/
https://www.ncbi.nlm.nih.gov/pubmed/33391515
http://dx.doi.org/10.7150/thno.51478

Ejemplares similares